Lineage Cell Therapeutics: Funding, Investors & Team (Oct 2026)
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. The company is focused on developing new therapeutics for age-related degenerative disease. BioTime and its subsidiaries are developing OpRegen® (a cell-based therapy for age-related macular degeneration), therapies for cancer, and arthritis, respectively. Our subsidiary ReCyte Therapeutics is using proprietary technology to reverse the developmental aging of human cells to manufacture young vascular progenitors for the treatment of age-related vascular disease. Relatively near-term product development by BioTime and its subsidiaries include Renevia, a patented hyaluronan-based hydrogel device for cell delivery; PanC-Dx, a blood-based pan-cancer screening diagnostic; and re-starting the embryonic stem cell-based clinical trial for spinal cord injury that was originally begun by Geron, using the stem cell assets acquired from them in 2013. BioTime also markets an FDA-approved blood plasma expander called Hextend®, which is currently marketed in collaboration with Hospira.
Lineage Cell Therapeutics has raised $92.0M across 4 funding rounds on record, the most recent an undisclosed round of $12.0M announced in Aug 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lineage Cell Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2025.
Lineage Cell Therapeutics Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
Lineage Cell Therapeutics announced an undisclosed round in May 2023; the amount was not disclosed.
9 months later, an undisclosed round of $14.0M was announced in Feb 2024.
9 months later, an undisclosed round of $66.0M was announced in Nov 2024.
9 months later, an undisclosed round of $12.0M was announced in Aug 2025.
Lineage Cell Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Lineage Cell Therapeutics Funding Compared to Other Biotechnology Startups
Lineage Cell Therapeutics' latest round of $12.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lineage Cell Therapeutics in Biotechnology and Carlsbad
Companies Similar to Lineage Cell Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Lineage Cell Therapeutics Funding FAQs
What does Lineage Cell Therapeutics do?
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. The company is focused on developing new therapeutics for age-related degenerative disease. BioTime and its subsidiaries are developing OpRegen® (a cell-based therapy for age-related macular degeneration), therapies for cancer, and arthritis, respectively. Our subsidiary ReCyte Therapeutics is using proprietary technology to reverse the developmental aging of human cells to manufacture young vascular progenitors for the treatment of age-related vascular disease. Relatively near-term product development by BioTime and its subsidiaries include Renevia, a patented hyaluronan-based hydrogel device for cell delivery; PanC-Dx, a blood-based pan-cancer screening diagnostic; and re-starting the embryonic stem cell-based clinical trial for spinal cord injury that was originally begun by Geron, using the stem cell assets acquired from them in 2013. BioTime also markets an FDA-approved blood plasma expander called Hextend®, which is currently marketed in collaboration with Hospira.
How much funding has Lineage Cell Therapeutics raised?
Lineage Cell Therapeutics has raised $92.0M across 4 rounds on record. The most recent is an undisclosed round of $12.0M announced in Aug 2025.
When did Lineage Cell Therapeutics last raise funding?
Lineage Cell Therapeutics' most recent funding round on record is an undisclosed round of $12.0M, announced in Aug 2025.
Who founded Lineage Cell Therapeutics?
FundedIQ lists Paul Segall (Founder) at Lineage Cell Therapeutics.
Who is the CEO of Lineage Cell Therapeutics?
Brian M Culley is listed as CEO at Lineage Cell Therapeutics.
Where is Lineage Cell Therapeutics headquartered?
Lineage Cell Therapeutics is based in Carlsbad, California, United States.
How many employees does Lineage Cell Therapeutics have?
Lineage Cell Therapeutics is in the 101-250 employee band.
How does Lineage Cell Therapeutics' funding compare to other Biotechnology startups?
Lineage Cell Therapeutics' latest round of $12.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Lineage Cell Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lineage Cell Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.